Physician profile
Ted Rogers
NPI 1467469759
$1,627.68
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $258 · 2021: $19.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $254.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.82 | 2019-2020 | |
| Abbvie INC. | $203.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $192.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $173.86 | 2019-2020 | |
| Astellas Pharma US INC | $104.12 | 2019-2020 | |
| Amgen INC. | $84.23 | 2019-2020 | |
| Pfizer INC. | $69.11 | 2019-2020 | |
| Lilly USA, LLC | $60.36 | 2019-2020 | |
| Novo Nordisk INC | $56.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.71 | 2019-2020 | |
| Allergan, INC. | $28.78 | 2019 | |
| Merck Sharp & Dohme LLC | $26.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.85 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.67 | 2019 | |
| Mylan Specialty L.P. | $14.23 | 2019 | |
| Phadia US INC. | $13.67 | 2020 | |
| Gilead Sciences, INC. | $13.41 | 2019 | |
| Circassia INC. | $11.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.